Natera (NTRA) announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera announces publication of Signatera validation study
- Humana initiated, Paycom upgraded: Wall Street’s top analyst calls
- Cautious Hold on Natera: Promising Growth Amid Valuation and Efficiency Concerns
- Natera initiated with an Equal Weight at Wells Fargo
- Natera price target raised to $268 from $255 at RBC Capital